Débora Barbosa Vendramini-Costa

Has grant

Associate Professor Research

Michigan State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Endoplasmic Reticulum Stress in the function of cancer associated fibroblasts in pancreatic cancer

Open Date: 2025-02-01

Close Date: 2030-01-31

Grant: Open

Netrin G1 Ligand: A New Immunomodulatory Target and Early Biomarker in Pancreatic Cancer

Open Date: 2023-07-01

Close Date: 2027-06-01

Articles (4)

Year:

2024

Pancreatic ductal adenocarcinoma is a deadly disease and is projected to become the second leading cause of cancer-related death by 2030. A major hallmark is the exuberant host response comprising the tumor microenvironment, of which, cancer-associated fibroblasts (CAF) are a prevalent component. Despite the gains in understanding of their heterogeneity and functionality from CAF studies in recent years, there are many unanswered questions surrounding this diverse population of cells. Here, we summarize the views of several experts in the field, focusing on the current understanding of CAFs and challenges to address.

Year:

2024

Pancreatic cancer is becoming increasingly deadly, with treatment options limited due to, among others, the complex tumor microenvironment (TME). This short communications study investigates pulsed low-dose-rate radiation (PLDR) as a potential alternative to conventional radiotherapy for pancreatic cancer neoadjuvant treatment. Our ex vivo research demonstrates that PLDR, in combination with chemotherapy, promotes a shift from tumor-promoting to tumor-suppressing properties in a key component of the pancreatic cancer microenvironment we called CAFu (cancer-associated fibroblasts and selfgenerated extracellular matrix functional units). This beneficial effect translates to reduced desmoplasia (fibrous tumor expansion) and suggests PLDR’s potential to improve total neoadjuvant therapy effectiveness. To comprehensively assess this functional shift, we developed the HOST-Factor, a single score integrating multiple biomarkers. This tool provides a more accurate picture of CAFu function compared to individual biomarkers and could be valuable for guiding and monitoring future therapeutic strategies. Our findings support the ongoing NCT04452357 clinical trial testing PLDR safety and TME normalization potential in pancreatic cancer patients. The HOST-Factor will be used in samples collected from this trial to validate its potential as a key tool for personalized medicine in this aggressive disease.

Year:

2024

Year:

2023

Collaborators (6)

Janusz Franco-Barraza

Assistant Research Professor

Fox Chase Cancer Center

UNITED STATES
View details

Ralph Francescone

Assistant Scientist/Assistant Professor

Fox Chase Cancer Center

UNITED STATES
View details

Howard Crawford

Professor

University of Michigan

UNITED STATES
View details

Marie Christin Hasselluhn

Associate Research Scientist

Columbia University Irving Medical Center

UNITED STATES
View details

Jaye Gardiner

Assistant Professor

Tufts University

UNITED STATES
View details

Aram F. Hezel

University of Rochester Medical Center

UNITED STATES
View details